O	0	10	Recurrence
O	11	13	of
O	14	20	breast
O	21	27	cancer
O	28	33	after
B-intervention	34	42	regional
I-intervention	43	45	or
I-intervention	46	53	general
I-intervention	54	65	anaesthesia
O	65	66	:
O	67	68	a
O	69	79	randomised
O	80	90	controlled
O	91	96	trial
O	96	97	.

O	98	103	Three
O	104	117	perioperative
O	118	125	factors
O	126	132	impair
O	133	137	host
O	138	145	defence
O	146	153	against
O	154	164	recurrence
O	165	171	during
O	172	178	cancer
O	179	186	surgery
O	186	187	:
O	188	191	the
O	192	200	surgical
O	201	207	stress
O	208	216	response
O	216	217	,
O	218	221	use
O	222	224	of
O	225	233	volatile
O	234	245	anaesthetic
O	245	246	,
O	247	250	and
O	251	258	opioids
O	259	262	for
O	263	272	analgesia
O	272	273	.

O	274	277	All
O	278	285	factors
O	286	289	are
O	290	301	ameliorated
O	302	304	by
O	305	313	regional
O	314	325	anaesthesia
O	325	326	-
O	326	335	analgesia
O	335	336	.

O	337	339	We
O	340	346	tested
O	347	350	the
O	351	358	primary
O	359	369	hypothesis
O	370	374	that
O	375	381	breast
O	382	388	cancer
O	389	399	recurrence
O	400	405	after
O	406	417	potentially
O	418	426	curative
O	427	434	surgery
O	435	437	is
O	438	443	lower
O	444	448	with
O	449	457	regional
O	458	469	anaesthesia
O	469	470	-
O	470	479	analgesia
O	480	485	using
O	486	499	paravertebral
O	500	506	blocks
O	507	510	and
O	511	514	the
O	515	526	anaesthetic
O	527	535	propofol
O	536	540	than
O	541	545	with
O	546	553	general
O	554	565	anaesthesia
O	566	570	with
O	571	574	the
O	575	583	volatile
O	584	595	anaesthetic
O	596	607	sevoflurane
O	608	611	and
O	612	618	opioid
O	619	628	analgesia
O	628	629	.

O	630	631	A
O	632	638	second
O	639	649	hypothesis
O	650	653	was
O	654	658	that
O	659	667	regional
O	668	679	anaesthesia
O	679	680	-
O	680	689	analgesia
O	690	697	reduces
O	698	708	persistent
O	709	719	incisional
O	720	724	pain
O	724	725	.

O	726	728	We
O	729	732	did
O	733	734	a
O	735	745	randomised
O	746	756	controlled
O	757	762	trial
O	763	765	at
O	766	768	13
O	769	778	hospitals
O	779	781	in
B-location	782	791	Argentina
I-location	791	792	,
I-location	793	800	Austria
I-location	800	801	,
I-location	802	807	China
I-location	807	808	,
I-location	809	816	Germany
I-location	816	817	,
I-location	818	825	Ireland
I-location	825	826	,
I-location	827	830	New
I-location	831	838	Zealand
I-location	838	839	,
I-location	840	849	Singapore
I-location	849	850	,
I-location	851	854	and
I-location	855	858	the
I-location	859	862	USA
O	862	863	.

O	864	869	Women
O	870	871	(
O	871	874	age
B-age	875	876	<
I-age	876	878	85
I-age	879	884	years
O	884	885	)
B-eligibility	886	892	having
I-eligibility	893	904	potentially
I-eligibility	905	913	curative
I-eligibility	914	921	primary
I-eligibility	922	928	breast
I-eligibility	929	935	cancer
I-eligibility	936	946	resections
O	947	951	were
O	952	962	randomised
O	963	965	by
O	966	974	computer
O	975	977	to
O	978	984	either
O	985	993	regional
O	994	1005	anaesthesia
O	1005	1006	-
O	1006	1015	analgesia
O	1016	1017	(
O	1017	1030	paravertebral
O	1031	1037	blocks
O	1038	1041	and
O	1042	1050	propofol
O	1050	1051	)
O	1052	1054	or
B-control	1055	1062	general
I-control	1063	1074	anaesthesia
O	1075	1076	(
O	1076	1087	sevoflurane
O	1087	1088	)
O	1089	1092	and
O	1093	1099	opioid
O	1100	1109	analgesia
O	1109	1110	.

O	1111	1114	The
O	1115	1122	primary
O	1123	1130	outcome
O	1131	1134	was
B-outcome-Measure	1135	1140	local
I-outcome-Measure	1141	1143	or
I-outcome-Measure	1144	1154	metastatic
I-outcome-Measure	1155	1161	breast
I-outcome-Measure	1162	1168	cancer
I-outcome-Measure	1169	1179	recurrence
O	1179	1180	.

O	1181	1184	The
O	1185	1194	secondary
O	1195	1202	outcome
O	1203	1206	was
B-outcome-Measure	1207	1217	incisional
I-outcome-Measure	1218	1222	pain
I-outcome-Measure	1223	1225	at
I-outcome-Measure	1226	1227	6
I-outcome-Measure	1228	1234	months
I-outcome-Measure	1235	1238	and
I-outcome-Measure	1239	1241	12
I-outcome-Measure	1242	1248	months
O	1248	1249	.

O	1250	1257	Primary
O	1258	1266	analyses
O	1267	1271	were
O	1272	1276	done
O	1277	1282	under
O	1283	1292	intention
O	1292	1293	-
O	1293	1295	to
O	1295	1296	-
O	1296	1301	treat
O	1302	1312	principles
O	1312	1313	.

O	1314	1318	This
O	1319	1324	trial
O	1325	1327	is
O	1328	1338	registered
O	1339	1343	with
O	1344	1358	ClinicalTrials
O	1358	1359	.
O	1359	1362	gov
O	1362	1363	,
O	1364	1375	NCT00418457
O	1375	1376	.

O	1377	1380	The
O	1381	1386	study
O	1387	1390	was
O	1391	1398	stopped
O	1399	1404	after
O	1405	1406	a
O	1407	1417	preplanned
O	1418	1426	futility
O	1427	1435	boundary
O	1436	1439	was
O	1440	1447	crossed
O	1447	1448	.

O	1449	1456	Between
O	1457	1460	Jan
O	1461	1463	30
O	1463	1464	,
O	1465	1469	2007
O	1469	1470	,
O	1471	1474	and
O	1475	1478	Jan
O	1479	1481	18
O	1481	1482	,
O	1483	1487	2018
O	1487	1488	,
B-total-participants	1489	1493	2132
O	1494	1499	women
O	1500	1504	were
O	1505	1513	enrolled
O	1514	1516	to
O	1517	1520	the
O	1521	1526	study
O	1526	1527	,
O	1528	1530	of
O	1531	1535	whom
O	1536	1538	24
O	1539	1543	were
O	1544	1552	excluded
O	1553	1559	before
O	1560	1567	surgery
O	1567	1568	.

B-intervention-participants	1569	1573	1043
O	1574	1578	were
O	1579	1587	assigned
O	1588	1590	to
O	1591	1599	regional
O	1600	1611	anaesthesia
O	1611	1612	-
O	1612	1621	analgesia
O	1622	1625	and
B-control-participants	1626	1630	1065
O	1631	1635	were
O	1636	1645	allocated
O	1646	1648	to
O	1649	1656	general
O	1657	1668	anaesthesia
O	1668	1669	.

O	1670	1678	Baseline
O	1679	1694	characteristics
O	1695	1699	were
O	1700	1704	well
O	1705	1713	balanced
O	1714	1721	between
O	1722	1727	study
O	1728	1734	groups
O	1734	1735	.

O	1736	1742	Median
O	1743	1749	follow
O	1749	1750	-
O	1750	1752	up
O	1753	1756	was
O	1757	1759	36
O	1760	1761	(
O	1761	1764	IQR
O	1765	1767	24
O	1767	1768	-
O	1768	1770	49
O	1770	1771	)
O	1772	1778	months
O	1778	1779	.

O	1780	1785	Among
O	1786	1791	women
O	1792	1800	assigned
O	1801	1809	regional
O	1810	1821	anaesthesia
O	1821	1822	-
O	1822	1831	analgesia
O	1831	1832	,
B-iv-bin-abs	1833	1836	102
O	1837	1838	(
B-iv-bin-percent	1838	1840	10
I-iv-bin-percent	1840	1841	%
O	1841	1842	)
B-outcome	1843	1854	recurrences
O	1855	1859	were
O	1860	1868	reported
O	1868	1869	,
O	1870	1878	compared
O	1879	1883	with
B-cv-bin-abs	1884	1887	111
O	1888	1889	(
B-cv-bin-percent	1889	1891	10
I-cv-bin-percent	1891	1892	%
O	1892	1893	)
O	1894	1905	recurrences
O	1906	1911	among
O	1912	1917	those
O	1918	1927	allocated
O	1928	1935	general
O	1936	1947	anaesthesia
O	1948	1949	(
O	1949	1955	hazard
O	1956	1961	ratio
O	1962	1963	0
O	1963	1964	·
O	1964	1966	97
O	1966	1967	,
O	1968	1970	95
O	1970	1971	%
O	1972	1974	CI
O	1975	1976	0
O	1976	1977	·
O	1977	1979	74
O	1979	1980	-
O	1980	1981	1
O	1981	1982	·
O	1982	1984	28
O	1984	1985	;
O	1986	1987	p
O	1987	1988	=
O	1988	1989	0
O	1989	1990	·
O	1990	1992	84
O	1992	1993	)
O	1993	1994	.

B-outcome	1995	2005	Incisional
I-outcome	2006	2010	pain
O	2011	2014	was
O	2015	2023	reported
O	2024	2026	by
B-iv-bin-abs	2027	2030	442
O	2031	2032	(
B-iv-bin-percent	2032	2034	52
I-iv-bin-percent	2034	2035	%
O	2035	2036	)
O	2037	2039	of
B-intervention-participants	2040	2043	856
O	2044	2052	patients
O	2053	2061	assigned
O	2062	2064	to
O	2065	2073	regional
O	2074	2085	anaesthesia
O	2085	2086	-
O	2086	2095	analgesia
O	2096	2099	and
B-cv-bin-abs	2100	2103	456
O	2104	2105	(
B-cv-bin-percent	2105	2107	52
I-cv-bin-percent	2107	2108	%
O	2108	2109	)
O	2110	2112	of
B-control-participants	2113	2116	872
O	2117	2125	patients
O	2126	2135	allocated
O	2136	2138	to
O	2139	2146	general
O	2147	2158	anaesthesia
B-outcome	2159	2161	at
I-outcome	2162	2163	6
I-outcome	2164	2170	months
O	2170	2171	,
O	2172	2175	and
O	2176	2178	by
B-iv-bin-abs	2179	2182	239
O	2183	2184	(
B-iv-bin-percent	2184	2186	28
I-iv-bin-percent	2186	2187	%
O	2187	2188	)
O	2189	2191	of
B-intervention-participants	2192	2195	854
O	2196	2204	patients
O	2205	2208	and
B-cv-bin-abs	2209	2212	232
O	2213	2214	(
B-cv-bin-percent	2214	2216	27
I-cv-bin-percent	2216	2217	%
O	2217	2218	)
O	2219	2221	of
B-control-participants	2222	2225	852
O	2226	2234	patients
O	2234	2235	,
O	2236	2248	respectively
O	2248	2249	,
B-outcome	2250	2252	at
I-outcome	2253	2255	12
I-outcome	2256	2262	months
O	2263	2264	(
O	2264	2271	overall
O	2272	2279	interim
O	2279	2280	-
O	2280	2288	adjusted
O	2289	2293	odds
O	2294	2299	ratio
O	2300	2301	1
O	2301	2302	·
O	2302	2304	00
O	2304	2305	,
O	2306	2308	95
O	2308	2309	%
O	2310	2312	CI
O	2313	2314	0
O	2314	2315	·
O	2315	2317	85
O	2317	2318	-
O	2318	2319	1
O	2319	2320	·
O	2320	2322	17
O	2322	2323	;
O	2324	2325	p
O	2325	2326	=
O	2326	2327	0
O	2327	2328	·
O	2328	2330	99
O	2330	2331	)
O	2331	2332	.

B-outcome	2333	2344	Neuropathic
I-outcome	2345	2351	breast
I-outcome	2352	2356	pain
O	2357	2360	did
O	2361	2364	not
O	2365	2371	differ
O	2372	2374	by
O	2375	2386	anaesthetic
O	2387	2396	technique
O	2397	2400	and
O	2401	2404	was
O	2405	2413	reported
O	2414	2416	by
B-iv-bin-abs	2417	2419	87
O	2420	2421	(
B-iv-bin-percent	2421	2423	10
I-iv-bin-percent	2423	2424	%
O	2424	2425	)
O	2426	2428	of
B-intervention-participants	2429	2432	859
O	2433	2441	patients
O	2442	2450	assigned
O	2451	2453	to
O	2454	2462	regional
O	2463	2474	anaesthesia
O	2474	2475	-
O	2475	2484	analgesia
O	2485	2488	and
B-cv-bin-abs	2489	2491	89
O	2492	2493	(
B-cv-bin-percent	2493	2495	10
I-cv-bin-percent	2495	2496	%
O	2496	2497	)
O	2498	2500	of
B-control-participants	2501	2504	870
O	2505	2513	patients
O	2514	2523	allocated
O	2524	2526	to
O	2527	2534	general
O	2535	2546	anaesthesia
B-outcome	2547	2549	at
I-outcome	2550	2551	6
I-outcome	2552	2558	months
O	2558	2559	,
O	2560	2563	and
O	2564	2566	by
B-iv-bin-abs	2567	2569	57
O	2570	2571	(
B-iv-bin-percent	2571	2572	7
I-iv-bin-percent	2572	2573	%
O	2573	2574	)
O	2575	2577	of
B-intervention-participants	2578	2581	857
O	2582	2590	patients
O	2591	2594	and
B-cv-bin-abs	2595	2597	57
O	2598	2599	(
B-cv-bin-percent	2599	2600	7
I-cv-bin-percent	2600	2601	%
O	2601	2602	)
O	2603	2605	of
B-control-participants	2606	2609	854
O	2610	2618	patients
O	2618	2619	,
O	2620	2632	respectively
O	2632	2633	,
B-outcome	2634	2636	at
I-outcome	2637	2639	12
I-outcome	2640	2646	months
O	2646	2647	.

O	2648	2650	In
O	2651	2654	our
O	2655	2660	study
O	2661	2671	population
O	2671	2672	,
O	2673	2681	regional
O	2682	2693	anaesthesia
O	2693	2694	-
O	2694	2703	analgesia
O	2704	2705	(
O	2705	2718	paravertebral
O	2719	2724	block
O	2725	2728	and
O	2729	2737	propofol
O	2737	2738	)
O	2739	2742	did
O	2743	2746	not
O	2747	2753	reduce
O	2754	2760	breast
O	2761	2767	cancer
O	2768	2778	recurrence
O	2779	2784	after
O	2785	2796	potentially
O	2797	2805	curative
O	2806	2813	surgery
O	2814	2822	compared
O	2823	2827	with
O	2828	2836	volatile
O	2837	2848	anaesthesia
O	2849	2850	(
O	2850	2861	sevoflurane
O	2861	2862	)
O	2863	2866	and
O	2867	2874	opioids
O	2874	2875	.

O	2876	2879	The
O	2880	2889	frequency
O	2890	2893	and
O	2894	2902	severity
O	2903	2905	of
O	2906	2916	persistent
B-outcome	2917	2927	incisional
I-outcome	2928	2934	breast
I-outcome	2935	2939	pain
O	2940	2943	was
O	2944	2954	unaffected
O	2955	2957	by
O	2958	2969	anaesthetic
O	2970	2979	technique
O	2979	2980	.

O	2981	2991	Clinicians
O	2992	2995	can
O	2996	2999	use
O	3000	3008	regional
O	3009	3011	or
O	3012	3019	general
O	3020	3031	anaesthesia
O	3032	3036	with
O	3037	3044	respect
O	3045	3047	to
O	3048	3054	breast
O	3055	3061	cancer
O	3062	3072	recurrence
O	3073	3076	and
O	3077	3087	persistent
O	3088	3098	incisional
O	3099	3103	pain
O	3103	3104	.

O	3105	3109	Sisk
O	3110	3120	Healthcare
O	3121	3131	Foundation
O	3132	3133	(
O	3133	3140	Ireland
O	3140	3141	)
O	3141	3142	,
O	3143	3149	Eccles
O	3150	3156	Breast
O	3157	3163	Cancer
O	3164	3172	Research
O	3173	3177	Fund
O	3177	3178	,
O	3179	3186	British
O	3187	3194	Journal
O	3195	3197	of
O	3198	3209	Anaesthesia
O	3210	3223	International
O	3223	3224	,
O	3225	3232	College
O	3233	3235	of
O	3236	3249	Anaesthetists
O	3250	3252	of
O	3253	3260	Ireland
O	3260	3261	,
O	3262	3268	Peking
O	3269	3274	Union
O	3275	3282	Medical
O	3283	3290	College
O	3291	3299	Hospital
O	3299	3300	,
O	3301	3308	Science
O	3309	3313	Fund
O	3314	3317	for
O	3318	3324	Junior
O	3325	3332	Faculty
O	3333	3337	2016
O	3337	3338	,
O	3339	3346	Central
O	3347	3351	Bank
O	3352	3354	of
O	3355	3362	Austria
O	3362	3363	,
O	3364	3367	and
O	3368	3376	National
O	3377	3387	Healthcare
O	3388	3393	Group
O	3393	3394	.
